Investigational Drug Information for XP19986
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug XP19986?
XP19986 is an investigational drug.
There have been 6 clinical trials for XP19986. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Gastroesophageal Reflux, Back Pain, and Spinal Cord Injuries. The leading clinical trial sponsors are Indivior Inc., XenoPort, Inc., and [disabled in preview].
Summary for XP19986
|US Patent Applications||124|
|WIPO Patent Applications||50|
|Japanese Patent Applications||15|
|Clinical Trial Progress||Phase 3 (2011-05-01)|
Recent Clinical Trials for XP19986
|Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis||Indivior Inc.||Phase 3|
|Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis||XenoPort, Inc.||Phase 3|
|A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)||Indivior Inc.||Phase 2|
Clinical Trial Summary for XP19986
Top disease conditions for XP19986
Top clinical trial sponsors for XP19986
US Patents for XP19986
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|